Monitoring therapeutic monoclonal antibodies in brain tumor

Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target ti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Ait-Belkacem, Rima, Berenguer, Caroline, Villard, Claude, Ouafik, L’Houcine, Figarella-Branger, Dominique, Beck, Alain, Chinot, Olivier, Lafitte, Daniel
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2014
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622724/
https://ncbi.nlm.nih.gov/pubmed/25484065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.34405
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars